FDA grants regular approval to Trodelvy for triple-negative breast cancer

979581

Sumary of FDA grants regular approval to Trodelvy for triple-negative breast cancer:

  • The FDA granted regular approval to sacituzumab govitecan for treatment of certain patients with triple-negative breast cancer..
  • The approval applies to use of the agent for patients with unresectable locally advanced or metastatic disease who received two or more prior systemic therapies, at least one of which was administered in the metastatic setting..
  • Sacituzumab govitecan (Trodelvy, Immunomedics) is an antibody-drug conjugate directed against Trop-2, a cell-surface protein expressed in many solid cancers..
  • Last year, the FDA granted accelerated approval to the agent for patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease..
  • The agency based the regular approval on results of a confirmatory randomized trial that included 529 patients with unresectable locally advanced or metastatic triple-negative breast cancer relapsed after at least two prior chemotherapies, one of which could be in the neoadjuvant or adjuvant setting if progression occurred within 12 months….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close